HealthyWay Inc.
健康之路股份有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2587)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

FINANCIAL HIGHLIGHTS

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Revenue	**775,323**	517,852
Gross profit	**243,162**	161,734
Gross profit margin	**31.4%**	31.2%
Profit for the period	**10,192**	7,040

The board (the "**Board**") of directors (the "**Director(s)**") of HealthyWay Inc. (the "**Company**") is pleased to announce the unaudited consolidated financial results of the Company and its subsidiaries (collectively, the "**Group**") for the six months ended 30 June 2026 (the "**Reporting Period**").

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

for the six months ended 30 June 2026 – unaudited

(Expressed in Renminbi)

		Six months ended 30 June	
		2026	2025
	Note	***RMB'000***	*RMB'000*
Revenue	*3*	**775,323**	517,852
Cost of sales		**(532,161)**	(356,118)
Gross profit		**243,162**	161,734
Other net income		**1,795**	1,161
Selling expenses		**(80,292)**	(87,249)
Administrative expenses		**(26,459)**	(26,256)
Research and development costs		**(127,569)**	(37,386)
Profit from operations		**10,637**	12,004
Finance cost		**(600)**	(1,358)
Share of profits less losses of associates		**(310)**	(148)
Profit before taxation		**9,727**	10,498
Income tax	*4*	**465**	(3,458)
Profit for the period		**10,192**	7,040
Attributable to:			
Equity shareholders of the Company		**9,161**	7,066
Non-controlling interests		**1,031**	(26)
Profit for the period		**10,192**	7,040
Earnings per share	*5*		
Basic and diluted *(RMB)*		**0.01**	0.01

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

for the six months ended 30 June 2026 – unaudited
(Expressed in Renminbi)

		Six months ended 30 June	
		2026	2025
	Note	***RMB'000***	*RMB'000*
Profit for the period		**10,192**	7,040
Other comprehensive income for the period			
Item that is or may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of overseas entities		**(4,089)**	1,338
Total comprehensive income for the period		**6,103**	8,378
Attributable to:			
Equity shareholders of the Company		**5,072**	8,404
Non-controlling interests		**1,031**	(26)
Total comprehensive income for the period		**6,103**	8,378

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

at 30 June 2026

(Expressed in Renminbi)

	Note	As at 30 June 2026 *RMB'000* (unaudited)	As at 31 December 2025 *RMB'000* (audited)
Non-current assets			
Property, plant and equipment		**14,278**	17,664
Intangible assets		**51,260**	58,975
Goodwill		**2,871**	2,871
Interests in associates		**8,700**	9,010
Deferred tax assets		**30,394**	26,235
		107,503	114,755
Current assets			
Inventories and other contract costs		**3,613**	2,464
Contract assets		**53**	136
Trade and other receivables	*6*	**317,474**	290,988
Prepayments		**25,737**	23,763
Restricted deposits		**140**	140
Cash and cash equivalents		**231,943**	271,512
		578,960	589,003
Current liabilities			
Trade and other payables	*7*	**297,193**	301,284
Contract liabilities		**59,079**	54,744
Loans and borrowings		**15,121**	31,238
Lease liabilities		**3,876**	3,589
Current taxation		**26,408**	23,369
		401,677	414,224
Net current assets		**177,283**	174,779

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
at 30 June 2026 (continued)
(Expressed in Renminbi)

	Note	As at 30 June 2026 RMB'000 (unaudited)	As at 31 December 2025 RMB'000 (audited)
Non-current liabilities			
Lease liabilities		**4,555**	6,353
Deferred tax liabilities		**294**	367
		4,849	6,720
NET ASSETS		**279,937**	282,814
CAPITAL AND RESERVES	*8*		
Share capital		**96**	96
Reserves		**271,212**	276,590
Total equity attributable to equity shareholders of the Company		**271,308**	276,686
Non-controlling interests		**8,629**	6,128
TOTAL EQUITY		**279,937**	282,814

NOTES TO THE FINANCIAL INFORMATION

(Expressed in Renminbi unless otherwise indicated)

1 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), including compliance with International Accounting Standard ("**IAS**") 34, *Interim financial reporting*, issued by the International Accounting Standards Board ("**IASB**"). It was authorised for issue on 28 August 2026.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in Note 2.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Company and its subsidiaries (the "**Group**") since the 2025 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with IFRS Accounting Standards.

2 CHANGES IN ACCOUNTING POLICIES

The IASB has issued a number of amendments to IFRS Accounting Standards that are first effective for the current accounting period. None of these developments have had a material effect on these financial statements. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

3 REVENUE AND SEGMENT REPORTING

(a) Revenue

The principal activities of the Group are providing corporate and digital marketing services and health and medical services.

(i) ***Disaggregation of revenue***

Disaggregation of revenue from contracts with customers by products at major service line and the timing of revenue recognition is as follows:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of IFRS 15		
Revenue recognised at a point in time		
– corporate and digital marketing services	**634,246**	372,946
– health and medical services	**35,189**	89,435
– others	**59**	155
	669,494	462,536
Revenue recognised over time		
– corporate and digital marketing services	**74,127**	40,113
– health and medical services	**28,536**	15,203
– others	**2,888**	–
	105,551	55,316
Total	**775,045**	517,852
Revenue from other resources		
Gross rentals from right-of-use assets	**278**	–
Total	**775,323**	517,852

(b) Segment reporting

The Group manages its businesses by service lines. In a manner consistent with the way in which information is reported internally to the Group's most senior executive management for the purposes of resource allocation and performance assessment, the Group has presented three separate segments as follows:

– Provision of corporate and digital marketing services ("**Corporate and digital marketing services**") which mainly consists of content services, information technology services and digital marketing services;

– Provision of health and medical services ("**Health and medical services**") which mainly consists of (i) medical support services; and (ii) value-based medical services; and

– Others.

For the purposes of assessing segment performance and allocating resources between segments, the Group's senior executive management monitors the results based on the revenue and gross profit of each segment.

No geographical segment analysis is presented as substantially all assets, liabilities, revenue and gross profit of the Group are attributable to the operations in Chinese Mainland.

(i) ***Reportable segment revenue and gross profit***

	Corporate and digital marketing services	Health and medical services	Others	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*
Six months ended 30 June 2026				
Revenue	**708,373**	**63,725**	**3,225**	**775,323**
Cost of sales	**(488,960)**	**(39,354)**	**(3,847)**	**(532,161)**
Reportable segment gross profit	**219,413**	**24,371**	**(622)**	**243,162**
Six months ended 30 June 2025				
Revenue	413,059	104,638	155	517,852
Cost of sales	(280,010)	(76,079)	(29)	(356,118)
Reportable segment gross profit	133,049	28,559	126	161,734

Substantially all of the Group's revenue were arising from Chinese Mainland. The Group does not allocate any specific assets or expenditure for property, plant and equipment to the operating segments as the Group's senior executive management does not use the information to measure the performance of the reportable segments.

(ii) ***Reconciliations of reportable segment profit or loss***

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Reportable segment gross profit	**243,162**	161,734
Other net income	**1,795**	1,161
Selling expenses	**(80,292)**	(87,249)
Administrative expenses	**(26,459)**	(26,256)
Research and development costs	**(127,569)**	(37,386)
Finance costs	**(600)**	(1,358)
Share of profits less losses of associates	**(310)**	(148)
Consolidated profit before taxation	**9,727**	10,498

4 INCOME TAX

Taxation in the consolidated statement of profit or loss represents:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Current tax		
Provision for the period	**3,767**	5,955
Deferred tax		
Origination and reversal of temporary differences	**(4,232)**	(2,497)
	(465)	3,458

Notes:

(i) Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Island, the Group is not subject to any income tax in the Cayman Islands and the British Virgin Island.

(ii) The provision for Hong Kong Profits Tax is calculated by applying the estimated annual effective tax rate of 16.5% (six months ended 30 June 2025: 16.5%). No provision has been made for Hong Kong Profits Tax as the Group did not have assessable profits for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

(iii) The Group's Chinese Mainland subsidiaries are subject to Corporate Income Tax ("**CIT**") at a statutory rate of 25% on their respective taxable income for the six months ended 30 June 2026 and 2025 except for certain subsidiaries mentioned in Notes (iv) and (v) below.

(iv) In accordance with the relevant PRC Corporate Income Tax Laws, regulations and implementation guidance notes, a subsidiary in Chinese Mainland was granted the Advanced and New Technology Enterprise Status for a valid period of 3 years from 2023 to 2025 which entitles the company to a reduced income tax rate at 15% during the valid period. The company has lodged application for the renewal of the High-tech Enterprise qualification and expected to obtain the approval by the end of 2026. Accordingly, the company is subject to PRC income tax at 15% for the six months ended 30 June 2026 on a provisional basis before the renewal of High-tech Enterprise qualification.

According to the relevant tax rules in the PRC, qualified research and development costs are allowed for bonus deduction for income tax purpose, as a result, an additional 100% of the qualified research and development costs could be deemed as deductible expenses for the six months ended 30 June 2026 and 2025.

(v) According to the PRC Corporate Income Tax Law and its implementation regulations, certain subsidiaries were qualified as "Small Low-profit Enterprise". These subsidiaries enjoyed a reduced corporate income tax rate of 20%.

5 EARNINGS PER SHARE

(a) Basic earnings per share

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of RMB9,161,000 (six months ended 30 June 2025: RMB7,066,000) and the weighted average of 876,779,000 ordinary shares (six months ended 30 June 2025: 877,705,000 shares) in issue during the Reporting Period.

Weighted average number of ordinary shares

	Six months ended 30 June	
	2026	2025
	'000	*'000*
Issued ordinary shares at 1 January	**877,653**	877,705
Effect of shares repurchased	**(874)**	–
Weighted average number of ordinary shares at 30 June	**876,779**	877,705

(b) Diluted earnings per share

For the six months ended 30 June 2026 and 2025, diluted earnings per share is the same as basic earnings per share as there were no dilutive potential ordinary shares.

6 TRADE AND OTHER RECEIVABLES

As of the end of the Reporting Period, the ageing analysis of trade receivables (which are included in trade and other receivables), based on the date of billing and net of loss allowance, is as follows:

	At 30 June	At 31 December
	2026	2025
	RMB'000	*RMB'000*
Within 1 month	**272,710**	260,659
More than 1 month but within 1 year	**30,071**	21,160
More than 1 year but within 2 years	**824**	977
More than 2 years but within 3 years	**298**	402
Trade receivables, net of loss allowance	**303,903**	283,198
Amounts due from related parties	**1,180**	1,070
Deposits	**3,656**	4,318
Other receivables	**8,735**	2,402
	317,474	290,988

7 TRADE AND OTHER PAYABLES

As of the end of the Reporting Period, the ageing analysis of trade creditors (which are included in trade and other payables), based on invoice date is as follows:

	At 30 June 2026 *RMB'000*	At 31 December 2025 *RMB'000*
Within 1 year	**238,413**	235,209
More than 1 year but within 2 years	**321**	226
More than 2 years but within 3 years	**13**	10
More than 3 years	**107**	106
Trade creditors	**238,854**	235,551
Salaries and bonus payables	**17,883**	23,903
Receipts in advance	**9,898**	11,220
Other payables	**30,558**	30,610
	297,193	301,284

8 CAPITAL, RESERVES AND DIVIDENDS

Dividends

The Directors do not recommend the payment of an interim dividend in respect of the Reporting Period (six months ended 30 June 2025: Nil).

Issued share capital

	At 30 June 2026		At 31 December 2025	
	Number of shares	**Share capital** *RMB'000*	Number of shares	Share capital *RMB'000*
Ordinary shares, issued and fully paid				
At 1 January	**876,683,300**	**96**	877,704,800	96
Shares repurchased *(Note (i))*	**(2,412,000)**	**–**	(1,021,500)	–
At 30 June/31 December	**874,271,300**	**96**	876,683,300	96

(i) ***Repurchase of own shares***

During the period, the Company repurchased its own ordinary shares on the Stock Exchange as follows:

Month/Year	**Number of shares repurchased**	**Highest price paid per share** *HKD*	**Lowest price paid per share** *HKD*	**Aggregate price paid (including transaction fee)** *HKD'000*
January 2026	1,694,000	5.06	4.91	8,430
April 2026	718,000	4.75	4.36	3,305
	2,412,000			11,735

The repurchased ordinary shares were treated as treasury shares as at 30 June 2026. The consideration paid on such repurchase of HKD11,735,000 (equivalent to RMB10,450,000) was fully paid and charged to treasury shares for the period ended 30 June 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

Overview

We operate a digital health and medical service platform in China. Since 2001, we have been providing health and medical services on digital platforms to individual users. In 2015, we expanded our services to corporations and institutions by providing corporate and digital marketing services.

For the Reporting Period, we continued to maintain our market presence and expanded our customer base. The number of registered individual users on our platform increased from 223.1 million as of 31 December 2025 to 229.8 million as of 30 June 2026. The number of our registered physicians increased from 934 thousand as of 31 December 2025 to 953 thousand as of 30 June 2026. Further, the number of hospitals connected to our platform increased from 12,870 as of 31 December 2025 to 17,047 as of 30 June 2026.

In addition, the Group commenced research on its AI Digital Employee Programme in 2023 and first launched its AI medical assistants and AI health managers in the market in 2025.

Our Services

The Group's services are primarily classified into two business segments, namely corporate and digital marketing services and health and medical services.

Corporate and digital marketing services

The Group's corporate and digital marketing services segment mainly consists of corporate services and digital marketing services. Corporate services provide content services and information technology services to corporate and institutional clients. The Group assists advertisers in promoting their products, services and brands on the Group's platforms and through other third-party online media channels.

During the Reporting Period, the Group experienced growth across key performance metrics in its corporate and digital marketing services. The Group's wellness content recorded 320 million views (corresponding period in 2025: 250 million views); the Group provided precision content services to 53 (corresponding period in 2025: 16) pharmaceutical companies and 17 (corresponding period in 2025: 9) other entities; and provided real world study services to 50 (corresponding period in 2025: 48) pharmaceutical companies and 15 (corresponding period in 2025: 6) other entities, completing 147 (corresponding period in 2025: 212) real world study reports.

During the Reporting Period, the number of corporate and institutional customers of the Group's information technology services was 257 (corresponding period in 2025: 258), while the number of advertisers for the Group's digital marketing services was 54 (corresponding period in 2025: 50).

Overall, as at 30 June 2026, the number of paying corporate and institutional customers for our corporate services and digital marketing services was 395 (as at 30 June 2025: 353).

Health and medical services

The Group's health and medical service segment primarily comprises medical support services and value-based medical services. Medical support services are designed to help individuals manage their daily health and wellness and are further divided into health membership schemes and other medical support services. Value-based medical services are designed to help patients and individuals in need who manage specific diseases and healthcare challenges.

During the Reporting Period, the Group continued to optimise its health and medical services portfolio by focusing on higher-value corporate healthcare solutions and AI-powered healthcare services. The Group provided health membership schemes to 1.8 million (corresponding period in 2025: 5.9 million) individual customers and 240 (corresponding period in 2025: 133) corporate customers; the number of online medical consultations arranged through the Group's platforms was 1.1 million (corresponding period in 2025: 1.4 million). In addition, the Group provided healthcare service packages to 0.43 million individual customers (corresponding period in 2025: 0.2 million). Even if the number of individual customers under health membership schemes decreased as compared with the corresponding period in 2025, the significant increase in corporate customers and the more than doubling of customers receiving healthcare service packages reflected the Group's strategic emphasis on enhancing service quality and customer value, as well as expanding its AI-enabled healthcare ecosystem.

Financial Review

Revenue

Set out below is a breakdown of our revenue by services, in both absolute amounts and as a percentage of our total revenue.

	Six months ended 30 June			
	2026		2025	
	RMB'000	*%*	*RMB'000*	*%*
Health and medical services				
Medical support services				
Health membership schemes	**63,007**	**8.1**	70,236	13.6
Other medical support services	**408**	**0.1**	4,845	0.9
Value-based medical services				
Healthcare service packages	**–**	**–**	119	0.0
Pharmaceutical sales business	**310**	**–***	29,438	5.7
Subtotal	**63,725**	**8.2**	104,638	20.2
Corporate and digital marketing services				
Corporate services				
Content services	**434,619**	**56.1**	250,665	48.4
Information technology services	**232,173**	**29.9**	122,647	23.7
Digital marketing services	**41,581**	**5.4**	39,747	7.7
Subtotal	**708,373**	**91.4**	413,059	79.8
Others	**3,225**	**0.4**	155	0.0
Total	**775,323**	**100.0**	517,852	100.0

* The percentage is less than 0.1%.

Our revenue increased by 49.7% from RMB517.9 million for the six months ended 30 June 2025 to RMB775.3 million for the Reporting Period, primarily due to (i) the increase in revenue from our content services from RMB250.7 million for the six months ended 30 June 2025 to RMB434.6 million and (ii) the increase in revenue from our information technology services from RMB122.6 million to RMB232.2 million, as our customer base continued to expand; while revenue in pharmaceutical sales business decreased as Jianmingtang Pharmacy

Chain Co., Ltd. (福建健明堂大藥房連鎖有限公司) ceased to be our subsidiary following its registered capital increase in the second half of 2025, after which its financial results were no longer consolidated into our financial statements.

Cost of Sales

Our total cost of sales increased by 49.5% from RMB356.1 million for the six months ended 30 June 2025 to RMB532.2 million for the Reporting Period, which is in line with its revenue growth.

Gross Profit and Gross Profit Margin

For the Reporting Period, our gross profit increased from RMB161.7 million for the six months ended 30 June 2025 to RMB243.2 million, which is in line with our revenue growth, and our gross profit margin remained relatively stable at 31.4% for the Reporting Period as compared to 31.2% for the six months ended 30 June 2025.

Other Net Income

Our other net income increased to RMB1.8 million for the Reporting Period from RMB1.2 million for the six months ended 30 June 2025, primarily due to the decrease in foreign exchange loss as compared with the corresponding period last year, partially offset by the decrease in interest income.

Selling Expenses

Our selling expenses decreased by 8.0% from RMB87.3 million for the six months ended 30 June 2025 to RMB80.3 million for the Reporting Period, mainly due to the decrease in remuneration expenditure for sales staff as compared with the corresponding period last year.

Administrative Expenses

Our administrative expenses remained relatively stable at RMB26.5 million for the Reporting Period as compared to RMB26.3 million for the six months ended 30 June 2025.

Research and Development Costs

Our research and development costs increased by 241.2% from RMB37.4 million for the six months ended 30 June 2025 to RMB127.6 million for the Reporting Period, primarily due to the Company's increased investment in research and development for its AI Agent (AI Digital Employees).

Finance Costs

Our finance costs decreased by 57.1% from RMB1.4 million for the six months ended 30 June 2025 to RMB0.6 million for the Reporting Period, mainly attributable to reduced bank borrowings and lower interest expenses.

Profit before Taxation

As a result of the foregoing, we recorded a profit before taxation of RMB9.7 million for the Reporting Period, as compared with a profit before taxation of RMB10.5 million for the six months ended 30 June 2025.

Income Tax

For the Reporting Period, we recorded income tax credit of RMB0.5 million, as compared to income tax expense of RMB3.5 million for the six months ended 30 June 2025, primarily due to the decrease in the current tax and provision of deferred tax.

Net Profit

As a result of the foregoing, we recorded a net profit of RMB10.2 million for the Reporting Period, as compared with a net profit of RMB7.0 million for the six months ended 30 June 2025.

Discussion of Selected Items in the Consolidated Balance Sheet

Current Assets and Liabilities

Our net current assets increased by 1.4% from RMB174.8 million as of 31 December 2025 to RMB177.3 million as of 30 June 2026, primarily due to the increase in trade and other receivables, partially offset by the decrease in loans and borrowings.

Inventories and Other Contract Costs

Our inventories primarily included medicines and health products. Our inventories and other contract costs increased from RMB2.5 million as of 31 December 2025 to RMB3.6 million as of 30 June 2026, primarily due to expenditures on projects not yet delivered recognised as contract performance costs and included in inventories and other contract costs.

Trade and Other Receivables

Our trade and other receivables increased from RMB291.0 million as of 31 December 2025 to RMB317.5 million as of 30 June 2026, which was mainly in line with the expansion of the Group's corporate and digital marketing services, primarily attributable to the increase in revenue from content services and information technology services, which resulted in an increase in trade receivables.

Prepayments

Our prepayments increased from RMB23.8 million as of 31 December 2025 to RMB25.7 million as of 30 June 2026, primarily due to the increase in prepayments for certain technical service projects and authoritative content services.

Trade and Other Payables

Our trade and other payables primarily include trade creditors, salaries and bonus payables, receipts in advance, and other payables. Our trade and other payables decreased to RMB297.2 million as of 30 June 2026 from RMB301.3 million as of 31 December 2025, primarily due to the decrease in payroll payable, partially offset by an increase in trade payables.

Contract Liabilities

Our contract liabilities mainly represent deposits received by the Group prior to the provision of the relevant services (mainly comprising healthcare services, corporate services and digital marketing services). Our contract liabilities were RMB59.1 million as of 30 June 2026 and at RMB54.7 million as of 31 December 2025. The slight increase was mainly attributable to the expansion of our business during the Reporting Period.

Contingent liabilities

We did not have any material contingent liabilities as of 30 June 2026 and as of 31 December 2025.

Non-Current Assets and Liabilities

Our total net assets of RMB282.8 million as of 31 December 2025 slightly decreased to RMB279.9 million as of 30 June 2026.

Our property, plant and equipment decreased from RMB17.7 million as of 31 December 2025 to RMB14.3 million as of 30 June 2026, primarily due to depreciation.

Our intangible assets decreased from RMB59.0 million as of 31 December 2025 to RMB51.3 million as of 30 June 2026, primarily because of the impact of amortisation.

Our goodwill remained stable at approximately RMB2.9 million as of 31 December 2025 and 30 June 2026.

Our non-current liabilities mainly represent lease liabilities with a remaining term of more than one year. Our non-current lease liabilities decreased from RMB6.4 million as at 31 December 2025 to RMB4.6 million as at 30 June 2026, primarily due to relevant rental payments.

Liquidity and Financial Resources

Set out below is a summary of our cash flows.

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Net cash (used in)/generated from operating activities	**(6,695)**	34,670
Net cash used in investing activities	**(592)**	(52,344)
Net cash used in financing activities	**(27,746)**	(11,130)
Net decrease in cash and cash equivalents	**(35,033)**	(28,804)
Cash and cash equivalents at 1 January	**271,512**	260,229
Effect of exchange rate changes	**(4,536)**	–
Cash and cash equivalents at 30 June	**231,943**	231,425

Our cash and cash equivalents remain relatively stable at RMB231.9 million as of 30 June 2026, as compared to RMB231.4 million as of 30 June 2025.

As of 30 June 2026, our total bank loans and borrowings amounted to RMB15.1 million as compared to RMB31.2 million as of 31 December 2025, as we repaid certain of our outstanding loans and borrowings during the Reporting Period. All loans and borrowings were denominated in RMB, carrying interest at rates ranging from 1.6% to 2.0% per annum (31 December 2025: 1.9% to 14.65%).

BUSINESS OUTLOOK AND PROSPECTS

Industry Status and Forecast

China's healthcare industry is at a critical stage marked by the deep integration of "Value-Based Healthcare" and "Digital Intelligence". Driven by increasingly stringent compliance requirements and the dual imperatives of cost reduction and efficiency enhancement, pharmaceutical companies continue to transform from traditional manpower-intensive marketing towards precise and digitally intelligent models. The adoption of AI technologies in healthcare settings is accelerating, while the application scenarios of real-world studies ("**RWS**") continue to expand, opening up new growth opportunities for digital health and medical services.

Strategic Focus and Cultivation of the Corporate Services Ecosystem

During the Reporting Period, revenue from the Group's corporate and digital marketing services segment increased by 71.6% from RMB413.1 million to RMB708.4 million, driving an approximately 49.7% year-on-year increase in overall revenue to RMB775.3 million and an approximately 50.3% year-on-year increase in gross profit to RMB243.2 million. Looking ahead, leveraging its network advantage of connecting more than 17,000 hospitals, the Group will continue to deepen its precision content services, RWS support services and information technology services, expand the breadth and depth of coverage of real-world clinical data, and consolidate the core competitive barriers of its enterprise service ecosystem.

Nationwide Ecosystem Expansion

To overcome the bottlenecks associated with regional coverage, the Group has progressively established regional ecosystem companies and collaborated with partners with established local customer bases, operational and execution capabilities and government resources to jointly promote the deployment and commercialisation of disease-specific platforms and AI projects across different regions, with the investment cost for each company ranging from approximately RMB0.5 million to RMB3.0 million. The pilot projects under this ecosystem expansion launched in Jiangsu and Sichuan in 2025 have demonstrated positive results. As at 30 June 2026, the Group had established seven regional ecosystem companies in Nanjing, Chengdu, Fuzhou, Guangzhou, Chongqing, Ningde and Wenzhou. Subsequent to the Reporting Period, the Group further established two companies in Guangxi and Wuhan.

Digital Intelligence-Driven Development

The Group will continue to increase its investment in the AI Agent (AI Digital Employees) initiative. As an AI-enabled system comprising AI sales assistants, AI medical assistants and AI health managers, AI Agent (AI Digital Employees) have performed specific operational and service functions throughout the healthcare service process, covering the entire chain from pre-consultation triage and in-consultation clinical support to post-consultation follow-up. They facilitate digital interactions between patients and doctors while accumulating real-world data assets. The Group commenced research and development of the AI Digital Employees program in 2023, and officially launched it in 2025, generating direct sales revenue of approximately RMB32.1 million for the first time in the year of 2025. In June 2026, the Board approved a change in the use of proceeds from the Global Offering, and reallocated part of the net proceeds to the research and development and deployment of AI Agent (AI Digital Employees) technologies, thereby accelerating the transformation of the business model from a labour-intensive model to a technology-driven model and enabling the Group to serve a broader range of pharmaceutical enterprise customers with a more competitive cost structure. For details, please see the Company's announcements dated 10 June 2026 and 29 July 2026.

Business Optimisation

In view of intensifying competition in the pharmaceutical retail industry, the Group has suspended further expansion of its offline specialty pharmacy network, with two underperforming pharmacies having been closed in the second half of 2025. The Group will continue to limit capital investment in low-margin businesses to ensure that its resources remain focused on strategic business segments with high growth potential and high profit margins.

Vision and Outlook

Looking ahead to the second half of the year, leveraging its continuously expanding healthcare network coverage, established enterprise service ecosystem, leading AI-driven digital intelligence applications and prudent capital allocation, the Group remains cautiously optimistic about its business prospects and will strive to achieve sustained improvements in both revenue scale and profitability, thereby creating long-term and sustainable value for its shareholders.

USE OF PROCEEDS

The net proceeds from the issue of new shares in the Company's global offering (after deducting underwriting commissions and related expenses) were approximately HK$109.4 million (equivalent to approximately RMB101.25 million) ("**Net Proceeds**").

As stated in the Company's announcements dated 10 June 2026 and 29 July 2026 in relation to the change of use of proceeds (the "**Announcements**"), after careful consideration and detailed evaluation by the Company of the latest business development, operational needs and current market conditions of the Group, in order to enhance capital efficiency and better support the long-term development strategy of the Group, the Board has resolved to reallocate part of the unutilised Net Proceeds.

As at 30 June 2026, details of the use of the unutilised Net Proceeds subsequent to the change in use are as follows:

Proposed Usage	Allocation of the Net Proceeds *(HK$ million)*	Utilised Net Proceeds from 30 December 2024, being the Listing Date, to 31 December 2025 *(HK$ million)*	Unutilised Net Proceeds as at 31 December 2025 *(HK$ million)*	Revised Allocation of the Unutilised Net Proceeds *(HK$ million)*	Utilised Net Proceeds during the Reporting Period *(HK$ million)*	Unutilised Net Proceeds as at 30 June 2026 *(HK$ million)*	Expected timelines for use of the Net Proceeds
1. Business Expansion	66.19	1.05	65.14	64.65	1.08	64.06	By December 2027
2. Strategic Investments or Acquisitions	22.97	0	22.97	22.97	0	22.97	By December 2027
3. Research and Development	15.86	0.8	15.06	14.69	0.5	14.56	By December 2027
4. Working Capital and General Corporate Purposes	4.38	0	4.38	4.38	0	4.38	By December 2027
Total	**109.4**	**1.85**	**107.55**	**106.69**	**1.58**	**105.97**	

Note: As of 10 June 2026, the total utilized Net Proceeds amounted to HK$2.71 million, while the unutilized Net Proceeds stood at HK$106.69 million. For details, please refer to the Announcements.

The Net Proceeds will be used in the manner consistent with the proposed allocations and expected timeline as disclosed in the Announcements.

MATERIAL EVENTS AFTER THE REPORTING PERIOD

As at the date of this announcement, there was no material event after the Reporting Period.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Board is committed to ensuring the Company adheres to a good standard of corporate governance. The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted and applied the principles as set out in the Corporate Governance Code (the "**CG Code**") contained in Appendix C1 to the Listing Rules as the basis of the Company's corporate governance practices. During the Reporting Period, the Company has complied with all the applicable code provisions as set out in CG Code, except for code deviation mentioned in the sub-section of "Chairman and Chief Executive Officer" below.

Chairman and Chief Executive Officer

Code provision C.2.1 of the CG Code stipulates that the role of chairman and chief executive officer should be separated and should not be performed by the same individual.

During the Reporting Period and up to the date of this announcement, Mr. Zhang Wanneng ("**Mr. Zhang**") serves as chairman of the Board and chief executive officer. Mr. Zhang is the founder of the Group and has been operating and managing the Group since incorporation. With extensive experience in the digital healthcare industry, Mr. Zhang is responsible for the overall management, decision-making and strategy planning of the Group and is instrumental to the Group's growth and business expansion since establishment.

Since Mr. Zhang is the key reason for the Group's development and he will not undermine the Group's interests in any way under any circumstances, the Board considers that vesting the roles of chairman and chief executive officer in the same person, Mr. Zhang, would not create any potential harm to the interest of the Group and it is, on the contrary, beneficial to the management of the Group.

In addition, the operation of the senior management and the Board, which comprises experienced individuals, effectively checks and balances the power and authority of Mr. Zhang, as both the chairman and chief executive officer of the Group. The Board currently comprises two executive Directors (including Mr. Zhang), one non-executive Director and three independent non-executive Directors and therefore has a fairly strong independence element in its composition.

The Company is committed to achieving high standard of corporate governance with a view to safeguarding the interests of our Shareholders. The Board will continue to review and consider splitting the roles of the chairman of the Board and the chief executive officer of the Company at a time when it is appropriate and suitable by taking into account the circumstances of the Group as a whole.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules. Specific enquiries have been made to all Directors and each of them has confirmed that they have complied with the Model Code during the Reporting Period.

REVIEW OF THE INTERIM RESULTS

The unaudited consolidated financial statements of the Group for the Reporting Period, including the accounting principles and practices adopted by the Group, have not been audited but have been reviewed by the Company's external auditor and by the Audit Committee of the Board, which as at the date of this announcement, consists of two independent non-executive directors and one non-executive director, namely Mr. Xu Jing, Ms. Deng Xiaolan and Mr. Wang Junfeng, with Mr. Xu Jing as the chairman of the Audit Committee.

INTERIM DIVIDEND

The Board did not recommend the distribution of an interim dividend for the Reporting Period (six months ended 2025: nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Reporting Period, the Company repurchased a total of 2,412,000 shares on the Stock Exchange for an aggregate consideration of approximately HKD11,710,660 (excluding transaction fees). The repurchased shares were subsequently held as treasury shares which may be cancelled, disposed of based on market conditions and the Group's capital needs, used as share awards as the Company sees fit or any other permitted purposes, in accordance with the Company's articles of association. The repurchase was effected for the Company's confidence in its business prospects and enhanced shareholder value.

Details of the shares repurchased are as follows:

Month of purchase during the Reporting Period	No. of shares purchased	Highest price paid *(HK$)*	Lowest price paid *(HK$)*	Aggregate consideration paid (excluding transaction fees) *(HK$)*
January	1,694,000	5.06	4.91	8,412,485
April	718,000	4.75	4.36	3,298,175
Total	2,412,000			11,710,660

The Company held 3,433,500 treasury shares as defined under the Listing Rules as at 30 June 2026.

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities during the Reporting Period.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.jkzlkj.cn. The interim report of the Company for the Reporting Period will be published on the aforesaid websites of the Stock Exchange and the Company in due course.

By order of the Board
HealthyWay Inc.
Zhang Wanneng
Chairman of the Board, executive director and chief executive officer

Hong Kong, 28 August 2026

As at the date of this announcement, the Board comprises Mr. Zhang Wanneng and Mr. Chen Jing as executive directors; Mr. Wang Junfeng as non-executive director; and Mr. Xu Jing, Dr. Lu Tao and Ms. Deng Xiaolan as independent non-executive directors.